Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 16, 2022

BUY
$13.15 - $20.45 $23,801 - $37,014
1,810 Added 1392.31%
1,940 $36,000
Q1 2022

May 16, 2022

SELL
$14.54 - $21.5 $6,746 - $9,976
-464 Reduced 78.11%
130 $2,000
Q4 2021

Feb 14, 2022

SELL
$20.24 - $36.01 $2,226 - $3,961
-110 Reduced 15.63%
594 $12,000
Q3 2021

Nov 16, 2021

BUY
$26.01 - $38.22 $5,306 - $7,796
204 Added 40.8%
704 $23,000
Q4 2020

Feb 16, 2021

BUY
$35.35 - $50.67 $17,675 - $25,335
500 New
500 $18,000
Q3 2020

Nov 17, 2020

SELL
$35.98 - $47.66 $17,990 - $23,830
-500 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$45.06 - $67.74 $22,530 - $33,870
500 New
500 $23,000

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $300M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Captrust Financial Advisors Portfolio

Follow Captrust Financial Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Captrust Financial Advisors with notifications on news.